Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage Oxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
Marketing Status approved; illicit; investigational
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 71335-0981; 67651-0304; 67651-0305; 67651-0306; 24510-140; 71335-1080; 0904-6966; 24510-130; 65162-048; 67877-625; 71335-0677; 65162-050; 0904-7180; 65162-047; 72162-1812; 67877-623; 67651-0302; 65162-049; 67651-0303; 65162-051; 24510-110; 24510-115; 71335-1023; 24510-120; 72162-1811
UNII CD35PMG570
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypogonadism05.05.04.002; 21.03.02.010---
Vasodilation procedure25.03.01.001---
Muscle relaxant therapy25.16.01.001---
Restless legs syndrome15.05.03.012; 17.02.07.008---
Disturbance in sexual arousal19.08.04.003---
Early satiety07.01.06.027; 08.01.09.004; 14.03.01.010---
Angiopathy24.03.02.007---
Metastases to central nervous system16.22.02.004; 17.02.10.013---
Urine output increased13.13.03.002---
Hepatic enzyme increased13.03.04.028---
Hot flush08.01.03.027; 21.02.02.001; 24.03.01.005--
Breast disorder21.05.04.004---
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Finger deformity15.10.03.003---
Infestation11.09.01.001; 23.11.01.002---
Intervertebral disc degeneration15.10.01.0020.000093%-
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.0020.004416%-
Abnormal behaviour19.01.01.001---
Decreased appetite08.01.09.028; 14.03.01.005--
Feeling of body temperature change08.01.09.0120.000091%-
Erectile dysfunction19.08.04.001; 21.03.01.007--
Psychiatric symptom19.01.02.001---
Ill-defined disorder08.01.03.049---
Inner ear disorder04.04.02.002---
Lacrimal disorder06.08.02.005---
Blood disorder01.05.01.004---
Adverse drug reaction08.06.01.009---
The 13th Page    First    Pre   13 14 15 16    Next   Last    Total 16 Pages